Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Temozolomide × Endocrine × Clear all

Phase

Status

Completed 7 Unknown 5 Active not recruiting 5 Withdrawn 2 Recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 68 Sarcoma 22 Dermatologic 13 Thoracic 5 Lymphoid 5 Breast 3 Other solid neoplasm 2 Genitourinary 2 Tumor-Agnostic 1 Other hematologic neoplasm 1 Gynecologic 1 Gastrointestinal 1 Endocrine 1 Classical hematology 1

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 8 lutetium Lu 177 dotatate 3 lanreotide 3 fosbretabulin 3 Sorafenib 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Capecitabine 3 surufatinib 2 pembrolizumab 2 pasireotide 2 lenvatinib 2 gallium Ga 68 dotatate 2 durvalumab 2 dactolisib 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Sunitinib 2 Panobinostat 2 Paclitaxel 2 Octreotide 2 Mitotane 2 Imatinib Mesylate 2 Fluorouracil 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Dexamethasone 2 Adrenalectomy 2 vandetanib 1 trifluridine tipiracil drug combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡